CDNA logo

CareDx Inc. (CDNA)

$74.56

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CDNA

Market cap

$3.92B

EPS

2.39

P/E ratio

30.7

Price to sales

7.19

Dividend yield

--

Beta

2.510135

Price on CDNA

Previous close

$73.72

Today's open

$74.26

Day's range

$72.02 - $75.53

52 week range

$15.15 - $90.87

Profile about CDNA

CEO

John W. Hanna

Employees

765

Headquarters

Brisbane, CA

Exchange

NASDAQ Global Market

Shares outstanding

52542786

Issue type

Common Stock

CDNA industries and sectors

Healthcare

Medical Diagnostics & Screening

News on CDNA

Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 28.1% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 17, 2026

news preview

ARK Invest Dumps These Shares While They're Hot, Buys Chips The Size Of Your Face

Cathie Wood's ARK Invest bought and sold medtech shares Friday. She also bought shares of an unconventional AI chipmaker — an unpopular one at that.

news source

Investors Business Daily • Nov 9, 2026

news preview

CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

news source

Zacks Investment Research • Nov 6, 2026

news preview

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock. The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniver.

news source

Business Wire • Nov 6, 2026

news preview

Baron Discovery Fund Q3 2026 Portfolio Activity

During the quarter, we initiated a position in Jersey Mike's Subs Inc., a franchisor of fast casual, submarine-style sandwich restaurants. We participated in the IPO of Lyntris Inc., a fast-growing proprietary defense solutions provider with a 90% sole-sourced portfolio exposed to many of the nation's key defense offerings. We sold our position in Wingstop Inc. during the quarter to allocate the proceeds into other restaurant companies where we felt there was better upside potential.

news source

Seeking Alpha • Nov 4, 2026

news preview

Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review

The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's relative performance in the quarter were Vishay Precision Group, Babcock & Wilcox, and CareDx (not held). The salient changes to positioning this quarter included our increased exposure to Health Care and decreased exposure to Industrials.

news source

Seeking Alpha • Nov 4, 2026

news preview

CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth

CDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.

news source

Zacks Investment Research • Nov 3, 2026

news preview

CareDx Announces Third KOAR Analysis Published in Transplantation

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation. The third manuscript from KOAR investigated the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and thr.

news source

Business Wire • Nov 3, 2026

news preview

Why CareDx Stock Soared Today

CareDx is a leader in the fast-growing field of medical diagnostics. The company is working to bring its non-invasive tests to new markets.

news source

The Motley Fool • Oct 30, 2026

news preview

CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript

CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CareDx Inc.

Open an M1 investment account to buy and sell CareDx Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CDNA on M1